Hypercalcemia in breast cancer. Reassessment of the mechanism

Carlos Isales, Maria L. Carcangiu, Andrew F. Stewart

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Hypercalcemia in patients with breast cancer is usually attributed to osteolytic bone metastases. Seventeen patients with biopsy-proved breast cancer and hypercalcemia were identified in a prospective, unselected manner. Biochemical and clinical evaluation included measurements of parathyroid hormone, nephrogenous cAMP, vitamin D metabolites, fasting calcium excretion, and maximal tubular phosphate reabsorption, and bone radionuclide scanning. Tumor histologic findings were also reviewed. Four of the 17 patients (23.5 percent) had no evidence of bone involvement by bone scanning or radiography. Two additional patients (a total of 35 percent) appeared to have a humoral component to their hypercalcemia as determined by the presence of elevated nephrogenous cAMP excretion. These observations suggest that humoral, tumor-derived products may play a more important role in the hypercalcemia of breast cancer than has been previously recognized.

Original languageEnglish (US)
Pages (from-to)1143-1147
Number of pages5
JournalThe American Journal of Medicine
Volume82
Issue number6
DOIs
StatePublished - Jun 1987

Fingerprint

Hypercalcemia
Breast Neoplasms
Bone and Bones
Parathyroid Hormone
Vitamin D
Radiography
Radioisotopes
Fasting
Neoplasms
Phosphates
Neoplasm Metastasis
Calcium
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hypercalcemia in breast cancer. Reassessment of the mechanism. / Isales, Carlos; Carcangiu, Maria L.; Stewart, Andrew F.

In: The American Journal of Medicine, Vol. 82, No. 6, 06.1987, p. 1143-1147.

Research output: Contribution to journalArticle

Isales, Carlos ; Carcangiu, Maria L. ; Stewart, Andrew F. / Hypercalcemia in breast cancer. Reassessment of the mechanism. In: The American Journal of Medicine. 1987 ; Vol. 82, No. 6. pp. 1143-1147.
@article{59fb1ab2ef454107a995ed92e0467df4,
title = "Hypercalcemia in breast cancer. Reassessment of the mechanism",
abstract = "Hypercalcemia in patients with breast cancer is usually attributed to osteolytic bone metastases. Seventeen patients with biopsy-proved breast cancer and hypercalcemia were identified in a prospective, unselected manner. Biochemical and clinical evaluation included measurements of parathyroid hormone, nephrogenous cAMP, vitamin D metabolites, fasting calcium excretion, and maximal tubular phosphate reabsorption, and bone radionuclide scanning. Tumor histologic findings were also reviewed. Four of the 17 patients (23.5 percent) had no evidence of bone involvement by bone scanning or radiography. Two additional patients (a total of 35 percent) appeared to have a humoral component to their hypercalcemia as determined by the presence of elevated nephrogenous cAMP excretion. These observations suggest that humoral, tumor-derived products may play a more important role in the hypercalcemia of breast cancer than has been previously recognized.",
author = "Carlos Isales and Carcangiu, {Maria L.} and Stewart, {Andrew F.}",
year = "1987",
month = "6",
doi = "10.1016/0002-9343(87)90216-6",
language = "English (US)",
volume = "82",
pages = "1143--1147",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Hypercalcemia in breast cancer. Reassessment of the mechanism

AU - Isales, Carlos

AU - Carcangiu, Maria L.

AU - Stewart, Andrew F.

PY - 1987/6

Y1 - 1987/6

N2 - Hypercalcemia in patients with breast cancer is usually attributed to osteolytic bone metastases. Seventeen patients with biopsy-proved breast cancer and hypercalcemia were identified in a prospective, unselected manner. Biochemical and clinical evaluation included measurements of parathyroid hormone, nephrogenous cAMP, vitamin D metabolites, fasting calcium excretion, and maximal tubular phosphate reabsorption, and bone radionuclide scanning. Tumor histologic findings were also reviewed. Four of the 17 patients (23.5 percent) had no evidence of bone involvement by bone scanning or radiography. Two additional patients (a total of 35 percent) appeared to have a humoral component to their hypercalcemia as determined by the presence of elevated nephrogenous cAMP excretion. These observations suggest that humoral, tumor-derived products may play a more important role in the hypercalcemia of breast cancer than has been previously recognized.

AB - Hypercalcemia in patients with breast cancer is usually attributed to osteolytic bone metastases. Seventeen patients with biopsy-proved breast cancer and hypercalcemia were identified in a prospective, unselected manner. Biochemical and clinical evaluation included measurements of parathyroid hormone, nephrogenous cAMP, vitamin D metabolites, fasting calcium excretion, and maximal tubular phosphate reabsorption, and bone radionuclide scanning. Tumor histologic findings were also reviewed. Four of the 17 patients (23.5 percent) had no evidence of bone involvement by bone scanning or radiography. Two additional patients (a total of 35 percent) appeared to have a humoral component to their hypercalcemia as determined by the presence of elevated nephrogenous cAMP excretion. These observations suggest that humoral, tumor-derived products may play a more important role in the hypercalcemia of breast cancer than has been previously recognized.

UR - http://www.scopus.com/inward/record.url?scp=0023615106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023615106&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(87)90216-6

DO - 10.1016/0002-9343(87)90216-6

M3 - Article

C2 - 3037897

AN - SCOPUS:0023615106

VL - 82

SP - 1143

EP - 1147

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -